Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024

Kura Oncology, Inc.

2023-FY EPS reported -$2.08

Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.
Cash and investments $424M at Dec 31, 2023; pro forma $570M after Jan 2024 private placement, runway into 2027.
Enrollment of 85 patients in registration-directed KOMET-001 trial of ziftomenib for NPM1-m AML expected by mid-2024.
Preliminary KOMET-007 data: 100% CR in frontline NPM1-m/KMT2A-r AML with 7+3; 53% ORR in R/R with ven/aza; no differentiation syndrome.
First patient dosed in KOMET-008 (ziftomenib + gilteritinib, FLAG-IDA or LDAC); collaboration with Mirati for KO-2806 + adagrasib.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Kura Oncology, Inc. reported financial results for fourth quarter and year ended December 31, 2023.

Period: fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.